Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Evaluate Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Sanofi Pasteur MSD
June 15, 2018
Snippet roundup: Panel says no to BTG and Sirtex says no to Varian
May 22, 2017
Astrazeneca's dealing cannot mask its problems
September 18, 2014
CureVac emerges with €35m cancer vaccine endorsement
July 29, 2014
KaloBios's stumbles provide a lesson to enthusiastic IPO investors
April 22, 2014
How oncology, vaccines and OTC will look after pharma’s game of musical chairs
November 05, 2013
Merck’s Gardasil follow-on succeeds but cost questions remain
September 19, 2013
EP Vantage interview – Major vaccines player takes a leaf out of pharma’s book
June 21, 2013
Event – Merck gears up for Gardasil successor
September 30, 2011
Merck's improved Gardasil could cause a stir
March 30, 2010
Product sales in 2009: hits and misses
September 10, 2009
Glaxo's US Cervarix approval more important for pride than sales
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
February 11, 2021
Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review
December 10, 2020
Evaluate Vantage 2021 Preview
Editor's Picks
February 10, 2021
2020 wins top of the froths for biotech stocks
October 04, 2018
Biotech flotations remain in high demand
February 04, 2021
Glaxo’s growth problem
January 27, 2021
Go or no go? Oncology decisions ahead for the FDA
February 05, 2021
Pfizer reveals its PD-1 secret
